The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

Cell Chemical Biology

Volumn 25, Issue 1, 2018, Pages 67-77.e3

  Burslem, George M ^a   Smith, Blake E ^a   Lai, Ashton C ^a   Jaime Figueroa, Saul ^a   McQuaid, Daniel C ^a   Bondeson, Daniel P ^a   Toure, Momar ^a   Dong, Hanqing ^b   Qian, Yimin ^b   Wang, Jing ^b   Crew, Andrew P ^b   Hines, John ^a   Crews, Craig M ^a  

^a YALE UNIVERSITY   (United States)

^b Arvinas Inc   (United States)

Author keywords

c Met; EGFR; HER2; PROTAC; receptor tyrosine kinases; targeted degradation; VHL

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; TUBULIN; ENZYME INHIBITOR; LIGAND; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; OVCAR-8 CELL LINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SK-BR-3 CELL LINE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CHIMERA; DRUG EFFECT; HUMAN; METABOLISM;

CHIMERA; ENZYME INHIBITORS; HUMANS; LIGANDS; PROTEOLYSIS; RECEPTOR PROTEIN-TYROSINE KINASES; UBIQUITIN-PROTEIN LIGASES;

EID: 85033410648     PISSN: 24519456     EISSN: 24519448     Source Type: Journal    
DOI: 10.1016/j.chembiol.2017.09.009     Document Type: Article

References (64)

1. Abella, J.V., Peschard, P., Naujokas, M.A., Lin, T., Saucier, C., Urbé S., Park, M., Met/hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for hrs phosphorylation. Mol. Cell. Biol. 25 (2005), 9632–9645.
2. Anido, J., Matar, P., Albanell, J., Guzmán, M., Rojo, F., Arribas, J., Averbuch, S., Baselga, J., ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin. Cancer Res. 9 (2003), 1274–1283.
3. Asaoka, Y., Tada, M., Ikenoue, T., Seto, M., Imai, M., Miyabayashi, K., Yamamoto, K., Yamamoto, S., Kudo, Y., Mohri, D., et al. Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion. Biochem. Biophys. Res. Commun. 394 (2010), 1042–1046.
4. Birchmeier, C., Birchmeier, W., Gherardi, E., Vande Woude, G.F., Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4 (2003), 915–925.
5. Bondeson, D.P., Mares, A., Smith, I.E.D., Ko, E., Campos, S., Miah, A.H., Mulholland, K.E., Routly, N., Buckley, D.L., Gustafson, J.L., et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11 (2015), 611–617.
6. Bondeson, D.P., Smith, B.E., Burslem, G.M., Buhimschi, A.D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B.D., Ishchenko, A., Crews, C.M., Lessons in PROTAC design from selective degradation with a promiscuous warhead. Cell. Chem. Biol. 25 (2017), 78–87 this issue.
7. Buckley, D.L., Gustafson, J.L., Van Molle, I., Roth, A.G., Tae, H.S., Gareiss, P.C., Jorgensen, W.L., Ciulli, A., Crews, C.M., Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α. Angew. Chem. Int. Ed. 51 (2012), 11463–11467.
8. Buckley, D.L., Raina, K., Darricarrere, N., Hines, J., Gustafson, J.L., Smith, I.E., Miah, A.H., Harling, J.D., Crews, C.M., HaloPROTACS: use of small molecule PROTACs to induce degradation of HaloTag fusion proteins. ACS Chem. Biol. 10 (2015), 1831–1837.
9. Buckley, D.L., Van Molle, I., Gareiss, P.C., Tae, H.S., Michel, J., Noblin, D.J., Jorgensen, W.L., Ciulli, A., Crews, C.M., Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1α interaction. J. Am. Chem. Soc. 134 (2012), 4465–4468.
10. Dassonville, O., Bozec, A., Fischel, J.L., Milano, G., EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Crit. Rev. Oncol. Hematol. 62 (2007), 53–61.
11. Douglass, E.F., Miller, C.J., Sparer, G., Shapiro, H., Spiegel, D.A., A comprehensive mathematical model for three-body binding equilibria. J. Am. Chem. Soc. 135 (2013), 6092–6099.
12. Drilon, A., MET exon 14 alterations in lung cancer: exon skipping extends half-life. Clin. Cancer Res. 22 (2016), 2832–2834.
13. Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J.O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007), 1039–1043.
14. Field, S.D., Arkin, J., Li, J., Jones, L.H., Selective downregulation of JAK2 and JAK3 by an ATP-competitive pan-JAK inhibitor. ACS Chem. Biol. 12 (2017), 1183–1187.
15. Gadd, M.S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D.J., Zengerle, M., Ciulli, A., Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat. Chem. Biol. 13 (2017), 514–521.
16. Gherardi, E., Birchmeier, W., Birchmeier, C., Woude, G.V., Targeting MET in cancer: rationale and progress. Nat. Rev. Cancer 12 (2012), 89–103.
17. Graves, Lee M., Duncan, James S., Whittle, Martin C., Johnson, Gary L., The dynamic nature of the kinome. Biochem. J. 450 (2013), 1–8.
18. Gschwind, A., Fischer, O.M., Ullrich, A., The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 4 (2004), 361–370.
19. Hines, J., Gough, J.D., Corson, T.W., Crews, C.M., Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs. Proc. Natl. Acad. Sci. USA 110 (2013), 8942–8947.
20. Hjerpe, R., Aillet, F., Lopitz-Otsoa, F., Lang, V., England, P., Rodriguez, M.S., Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. EMBO Rep. 10 (2009), 1250–1258.
21. Iqbal, N., Iqbal, N., Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic Implications. Mol. Biol. Int., 2014, 2014, 852748.
22. Jo, M., Stolz, D.B., Esplen, J.E., Dorko, K., Michalopoulos, G.K., Strom, S.C., Cross-talk between epidermal growth factor receptor and c-met signal pathways in transformed cells. J. Biol. Chem. 275 (2000), 8806–8811.
23. Joffre, C., Barrow, R., Menard, L., Calleja, V., Hart, I.R., Kermorgant, S., A direct role for Met endocytosis in tumorigenesis. Nat. Cell Biol. 13 (2011), 827–837.
24. Kermorgant, S., Zicha, D., Parker, P.J., Protein kinase C controls microtubule-based traffic but not proteasomal degradation of c-met. J. Biol. Chem. 278 (2003), 28921–28929.
25. Kim, K.B., Fonseca, F.N., Crews, C.M., Development and characterization of proteasome inhibitors. Methods Enzymol. 399 (2005), 585–609.
26. Koga, F., Tsutsumi, S., Neckers, L.M., Low dose geldanamycin inhibits hepatocyte growth factor- and hypoxia-stimulated invasion of cancer cells. Cell Cycle 6 (2007), 1393–1402.
27. Konecny, G.E., Pegram, M.D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D.W., Spehar, G., Mullin, R.J., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66 (2006), 1630–1639.
28. Kong-Beltran, M., Seshagiri, S., Zha, J., Zhu, W., Bhawe, K., Mendoza, N., Holcomb, T., Pujara, K., Stinson, J., Fu, L., et al. Somatic mutations lead to an oncogenic deletion of Met in lung cancer. Cancer Res. 66 (2006), 283–289.
29. Kurimchak, A.M., Shelton, C., Duncan, K.E., Johnson, K.J., Brown, J., O'Brien, S., Gabbasov, R., Fink, L.S., Li, Y., Lounsbury, N., et al. Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer. Cell Rep. 16 (2016), 1273–1286.
30. Lai, A.C., Toure, M., Hellerschmied, D., Salami, J., Jaime-Figueroa, S., Ko, E., Hines, J., Crews, C.M., Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew. Chem. Int. Ed. 55 (2016), 807–810.
31. Lebraud, H., Wright, D.J., Johnson, C.N., Heightman, T.D., Protein degradation by in-cell self-assembly of proteolysis targeting chimeras. ACS Cent. Sci. 2 (2016), 927–934.
32. Lemmon, M.A., Schlessinger, J., Cell signaling by receptor tyrosine kinases. Cell 141 (2010), 1117–1134.
33. Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J.D., Crew, A.P., Coleman, K., et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22 (2015), 755–763.
34. Mahalingam, D., Swords, R., Carew, J.S., Nawrocki, S.T., Bhalla, K., Giles, F.J., Targeting HSP90 for cancer therapy. Br. J. Cancer 100 (2009), 1523–1529.
35. Miyajima, N., Tsutsumi, S., Sourbier, C., Beebe, K., Mollapour, M., Rivas, C., Yoshida, S., Trepel, J.B., Huang, Y., Tatokoro, M., et al. The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. Can. Res. 73 (2013), 7022–7033.
36. Neklesa, T.K., Crews, C.M., Chemical biology: greasy tags for protein removal. Nature 487 (2012), 308–309.
37. Neklesa, T.K., Tae, H.S., Schneekloth, A.R., Stulberg, M.J., Corson, T.W., Sundberg, T.B., Raina, K., Holley, S.A., Crews, C.M., Small-molecule hydrophobic tagging–induced degradation of HaloTag fusion proteins. Nat. Chem. Biol. 7 (2011), 538–543.
38. Organ, S.L., Tsao, M.-S., An overview of the c-MET signaling pathway. Ther. Adv. Med. Oncol. 3 (2011), S7–S19.
39. Pellinen, T., Arjonen, A., Vuoriluoto, K., Kallio, K., Fransen, J.A.M., Ivaska, J., Small GTPase Rab21 regulates cell adhesion and controls endosomal traffic of β1-integrins. J. Cell Biol. 173 (2006), 767–780.
40. Perez-Torres, M., Guix, M., Gonzalez, A., Arteaga, C.L., Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. J. Biol. Chem. 281 (2006), 40183–40192.
41. Peschard, P., Fournier, T.M., Lamorte, L., Naujokas, M.A., Band, H., Langdon, W.Y., Park, M., Mutation of the c-cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8 (2001), 995–1004.
42. Pillay, V., Allaf, L., Wilding, A.L., Donoghue, J.F., Court, N.W., Greenall, S.A., Scott, A.M., Johns, T.G., The plasticity of oncogene addiction: Implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 11 (2009), 448–458.
43. Pratz, K.W., Cortes, J., Roboz, G.J., Rao, N., Arowojolu, O., Stine, A., Shiotsu, Y., Shudo, A., Akinaga, S., Small, D., et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood 113 (2009), 3938–3946.
44. Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A.M.K., Wang, J., Chen, X., Dong, H., Siu, K., et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc. Natl. Acad. Sci. USA 113 (2016), 7124–7129.
45. Sakamoto, K.M., Kim, K.B., Kumagai, A., Mercurio, F., Crews, C.M., Deshaies, R.J., Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. USA 98 (2001), 8554–8559.
46. Scagliotti, G., Pawel, J.v., Novello, S., Ramlau, R., Favaretto, A., Barlesi, F., Akerley, W., Orlov, S., Santoro, A., Spigel, D., et al. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 33 (2015), 2667–2674.
47. Schiedel, M., Herp, D., Hammelmann, S., Swyter, S., Lehotzky, A., Robaa, D., Oláh, J., Ovádi, J., Sippl, W., Jung, M., Chemically induced degradation of sirtuin 2 (Sirt2) by a Proteolysis targeting Chimera (PROTAC) based on sirtuin rearranging ligands (SirReals). J. Med. Chem., 2017, 10.1021/acs.jmedchem.6b01872.
48. Schneekloth, A.R., Pucheault, M., Tae, H.S., Crews, C.M., Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics. Bioorg. Med. Chem. Lett. 18 (2008), 5904–5908.
49. Sequist, L.V., Pawel, J.v., Garmey, E.G., Akerley, W.L., Brugger, W., Ferrari, D., Chen, Y., Costa, D.B., Gerber, D.E., Orlov, S., et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J. Clin. Oncol. 29 (2011), 3307–3315.
50. Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., Adolf, G.R., Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. Pharmacol. Exp. Ther. 343 (2012), 342–350.
51. Soucy, T.A., Smith, P.G., Milhollen, M.A., Berger, A.J., Gavin, J.M., Adhikari, S., Brownell, J.E., Burke, K.E., Cardin, D.P., Critchley, S., et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458 (2009), 732–736.
52. Stuhlmiller, T.J., Miller, S.M., Zawistowski, J.S., Nakamura, K., Beltran, A.S., Duncan, J.S., Angus, S.P., Collins, K.A.L., Granger, D.A., Reuther, R.A., et al. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Rep. 11 (2015), 390–404.
53. Takeuchi, K., Ito, F., Receptor tyrosine kinases and targeted cancer therapeutics. Biol. Pharm. Bull. 34 (2011), 1774–1780.
54. Thelemann, A., Petti, F., Griffin, G., Iwata, K., Hunt, T., Settinari, T., Fenyo, D., Gibson, N., Haley, J.D., Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol. Cell. Proteomics 4 (2005), 356–376.
55. Tsao, M.-S., Yang, Y., Marcus, A., Liu, N., Mou, L., Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. Hum. Pathol. 32 (2001), 57–65.
56. Wang, S., Pashtan, I., Tsutsumi, S., Xu, W., Neckers, L., Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors. Cell Cycle 8 (2009), 2050–2056.
57. Wislez, M., Domblides, C., Cortot, A., Lemoine, A., Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas?. Ann. Transl. Med., 4, 2016, 96.
58. Xie, T., Lim, S.M., Westover, K.D., Dodge, M.E., Ercan, D., Ficarro, S.B., Udayakumar, D., Gurbani, D., Tae, H.S., Riddle, S.M., et al. Pharmacological targeting of the pseudokinase Her3. Nat. Chem. Biol. 10 (2014), 1006–1012.
59. Xu, A.M., Huang, P.H., Receptor tyrosine kinase coactivation networks in cancer. Can. Res. 70 (2010), 3857–3860.
60. Yasuda, H., Park, E., Yun, C.-H., Sng, N.J., Lucena-Araujo, A.R., Yeo, W.-L., Huberman, M.S., Cohen, D.W., Nakayama, S., Ishioka, K., et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci. Transl. Med., 5, 2013, 216ra177.
61. Yewale, C., Baradia, D., Vhora, I., Patil, S., Misra, A., Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials 34 (2013), 8690–8707.
62. Zengerle, M., Chan, K.-H., Ciulli, A., Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem. Biol. 10 (2015), 1770–1777.
63. Zhou, B., Hu, J., Xu, F., Chen, Z., Bai, L., Fernandez-Salas, E., Lin, M., Liu, L., Yang, C.-Y., Zhao, Y., et al. Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J. Med. Chem., 2017, 10.1021/acs.jmedchem.6b01816 Article ASAP.
64. Zillhardt, M., Park, S.-M., Romero, I.L., Sawada, K., Montag, A., Krausz, T., Yamada, S.D., Peter, M.E., Lengyel, E., Foretinib (GSK1363089), an orally available multikinase inhibitor of c-met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin. Cancer Res. 17 (2011), 4042–4051.